Viatris Inc. VTRS
21.06 USD +0.21 (+1.01%)
At closeNov 12, 2026, 6:47 AM EST
21.20 +0.14 +0.66%
Pre-market · Nov 12, 6:47 AM ET
20.60 Day range 21.10
10.15 52-week range 21.10
- YTD
- +69.16%
- 1 year
- +91.28%
News
prnewswire.com Viatris to Participate in Upcoming Investor Conferences PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare…
zacks.com VTRS or DHR: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue? Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
businesswire.com Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
zacks.com Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 Earnings The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
seekingalpha.com Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
zacks.com Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
benzinga.com Viatris Q3 2026 Earnings Call Transcript Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Viatris (VTRS) Q3 Earnings Beat Estimates Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.
benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 analyst estimate. Narrows FY2026 sales outlook from $14.550 billion-$14.950 billion to $14.700…
prnewswire.com Viatris Reports Third-Quarter 2026 Financial Results Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in…
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
benzinga.com Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the…
finance.sina.com.cn VTRS收涨1.01%，成交额3.02亿美元 该公司销售品牌药和仿制药，包括复杂药物。该公司的分部包括发达市场、大中华区、JANZ以及新兴市场。发达市场分部主要包括北美和欧洲业务。大中华区分部包括中国大陆、台湾和中国香港业务。JANZ分部包括日本、澳大利亚和新西兰业务。新兴市场分部覆盖125多个国家的发展中市场和新兴经济体，包括亚洲、非洲、东欧、拉丁美洲和中东，以及该公司的抗逆转录病毒（ARV）业务。该公司在多个主要治疗领域提供药品，从心血管…- finance.sina.com.cn NuShares ESG Small-Cap ETF前十大重仓股占比10.3721%，第一大重仓股为VTRS 数据显示，NuShares ESG Small-Cap ETF前十大重仓股合计占基金资产的10.3721%。 其中，第一大重仓股为VTRS，持仓占比1.2802%；第二大重仓股为Nextpower Inc ORD，占比1.1573%；第三大重仓股为美国豪斯特酒店，占比1.1171%。 此外，前十大重仓股还包括RenaissanceRe Holdings…
finance.yahoo.com David Einhorn’s Best Buy Is Already Up 36%. Is It Too Late to Follow Him? Key TakeawaysPayPal is up 36% since June 30, the best of the seven stocks David Einhorn’s Greenlight Capital bought or added ...
finance.yahoo.com Ingram Micro jumps after securing spot in S&P SmallCap 600 Ingram Micro Holding Ltd (NYSE:INGM) shares climbed 4.8% in extended trading Wednesday after S&P Dow Jones Indices announced the technology distributor will join the S&P SmallCap 600. The Irvine, ...seekingalpha.com Buy 18 Ideal 'Safer' November Dividend Dogs Of 10-Year Tenured 81 Read the list of five low-priced, high-yield tenured dividend dogs stock picks as potential outperformers, with 53.49% net ...
- streetinsider.com Ingram Micro Holding Set to Join S&P SmallCap 600 Following is a summary of the changes that will take place prior to the open of trading on the effective date: S&P Dow Jones Indices is the largest global resource for essential index-based concepts,…